6678 — Techno Medica Co Income Statement
0.000.00%
- ¥13bn
- ¥4bn
- ¥10bn
- 96
- 82
- 63
- 95
Annual income statement for Techno Medica Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9,811 | 9,040 | 9,699 | 9,368 | 10,284 |
Cost of Revenue | |||||
Gross Profit | 4,498 | 4,454 | 4,817 | 4,630 | 5,152 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 8,484 | 7,413 | 7,837 | 7,721 | 8,444 |
Operating Profit | 1,327 | 1,627 | 1,862 | 1,647 | 1,840 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,339 | 1,649 | 1,851 | 1,666 | 1,861 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,000 | 1,153 | 1,281 | 1,151 | 1,348 |
Net Income Before Extraordinary Items | |||||
Net Income | 1,000 | 1,153 | 1,281 | 1,151 | 1,348 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,000 | 1,153 | 1,281 | 1,151 | 1,348 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 112 | 134 | 151 | 137 | 174 |
Dividends per Share |